Main takeaway: Aroa is forecasting a surge in revenue and profits in its second half as new products hit the market.
Aroa Biosurgery founder and chief executive Brian Ward believes the ASX-listed company is undervalued by the market and is forecasting a surge in second-half revenues of up to 40% as the company’s investment in new product starts to pay off.
Aroa, a regenerative medicine company founded in
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
